Frequency of cancer testis antigens in chronic myeloid leukemia

Revista Medica del Hospital General de Mexico Pub Date : 2016-04-01 DOI:10.1016/j.hgmx.2015.10.003

I. Mendoza-Salas , I. Olarte-Carrillo , E. Miranda-Peralta , C. Ramos-Peñafiel , A. García-Laguna , R. Cerón-Maldonado , A. De la Cruz-Rosas , J. Collazo-Jaloma , J. Kassac-Ipiña , E. Mendoza-García , E. Ramón-Gallegos , A. Martínez-Tovar

{"title":"Frequency of cancer testis antigens in chronic myeloid leukemia","authors":"I. Mendoza-Salas , I. Olarte-Carrillo , E. Miranda-Peralta , C. Ramos-Peñafiel , A. García-Laguna , R. Cerón-Maldonado , A. De la Cruz-Rosas , J. Collazo-Jaloma , J. Kassac-Ipiña , E. Mendoza-García , E. Ramón-Gallegos , A. Martínez-Tovar","doi":"10.1016/j.hgmx.2015.10.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Cancer testis antigens (CTA) are expressed in several types of cancer but not in normal adult tissue, with the exception of testicular germ cells, and for this reason are considered targets for immunotherapy.</p></div><div><h3>Objective</h3><p>The aim of this study was to determine the frequency and clinical significance of CTA expression in cells from patients with chronic myeloid leukaemia (CML).</p></div><div><h3>Materials and methods</h3><p>We analysed 8 genes of the CTA family (MAGE-A3, MAGE-A4, MAGE-B2 MAGE-C1, BAGE-1, GAGE-2, LAGE-1 and NY-ESO-1) in 10 peripheral blood samples from healthy donors and 65 bone marrow samples from CML patients using reverse transcriptase polymerase chain reaction (RT-PCR). Eleven samples from hematopoietic progenitor stem cells from patients receiving conventional treatment (hydroxyurea and INFα) and 21 samples from patients receiving tyrosine kinase inhibitors (Imatinib, Nilotinib, Dasatinib) were analysed.</p></div><div><h3>Results</h3><p>Frequency of CTA genes in CML patients was 32.3%, 63.0%, 1.5%, 3.0%, 6.1%, 20.0%, 13.8% and 36.9% for MAGE-A3, MAGE-A4, MAGE-B2, MAGE C1, BAGE, GAGE, LAGE and NY-ESO, respectively. The correlation between expression and clinical parameters showed statistical significance in the MAGE-A3 genes in sex (<em>p</em>  =0.014) in platelets (<em>p</em>  =0.001). The hematopoietic progenitor stem cells from patients in treatment showed a higher frequency of expression than <em>de novo</em> patients. In patients receiving conventional drugs (CD), frequency of MAGE-A3 expression was 50%, and 69.2% with TKI, MAGE-A4 frequency was 20% with CD and 53.8% with TKI. Finally, frequency of NY-ESO-1 was 20% with CD and 0% with TKI. The frequency of MAGE-A4 expression was highest, followed by MAGE-A3, NY-ESO-1, GAGE-2, LAGE-1, BAGE-1, MAGE-B2 and MAGE-C1.</p></div><div><h3>Conclusion</h3><p>Detection of CTA genes by molecular biology techniques is important due to their use as biomarkers in LMC, in the monitoring of disease progression and in patients who are resistant to chemotherapy. The frequency of CTA expression in treated and <em>de novo</em> differs significantly.</p></div>","PeriodicalId":31559,"journal":{"name":"Revista Medica del Hospital General de Mexico","volume":"79 2","pages":"Pages 46-54"},"PeriodicalIF":0.0000,"publicationDate":"2016-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.hgmx.2015.10.003","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Medica del Hospital General de Mexico","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0185106315000888","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 2

Abstract

Background

Cancer testis antigens (CTA) are expressed in several types of cancer but not in normal adult tissue, with the exception of testicular germ cells, and for this reason are considered targets for immunotherapy.

Objective

The aim of this study was to determine the frequency and clinical significance of CTA expression in cells from patients with chronic myeloid leukaemia (CML).

Materials and methods

We analysed 8 genes of the CTA family (MAGE-A3, MAGE-A4, MAGE-B2 MAGE-C1, BAGE-1, GAGE-2, LAGE-1 and NY-ESO-1) in 10 peripheral blood samples from healthy donors and 65 bone marrow samples from CML patients using reverse transcriptase polymerase chain reaction (RT-PCR). Eleven samples from hematopoietic progenitor stem cells from patients receiving conventional treatment (hydroxyurea and INFα) and 21 samples from patients receiving tyrosine kinase inhibitors (Imatinib, Nilotinib, Dasatinib) were analysed.

Results

Frequency of CTA genes in CML patients was 32.3%, 63.0%, 1.5%, 3.0%, 6.1%, 20.0%, 13.8% and 36.9% for MAGE-A3, MAGE-A4, MAGE-B2, MAGE C1, BAGE, GAGE, LAGE and NY-ESO, respectively. The correlation between expression and clinical parameters showed statistical significance in the MAGE-A3 genes in sex (p = 0.018), MAGE-C1 in leukocytes (p = 0.014) in platelets (p = 0.002), and finally LAGE-1, which was associated with platelets (p = 0.001). The hematopoietic progenitor stem cells from patients in treatment showed a higher frequency of expression than de novo patients. In patients receiving conventional drugs (CD), frequency of MAGE-A3 expression was 50%, and 69.2% with TKI, MAGE-A4 frequency was 20% with CD and 53.8% with TKI. Finally, frequency of NY-ESO-1 was 20% with CD and 0% with TKI. The frequency of MAGE-A4 expression was highest, followed by MAGE-A3, NY-ESO-1, GAGE-2, LAGE-1, BAGE-1, MAGE-B2 and MAGE-C1.

Conclusion

Detection of CTA genes by molecular biology techniques is important due to their use as biomarkers in LMC, in the monitoring of disease progression and in patients who are resistant to chemotherapy. The frequency of CTA expression in treated and de novo differs significantly.

查看原文本刊更多论文

慢性髓系白血病中癌睾丸抗原的频率

肿瘤睾丸抗原(CTA)在几种类型的癌症中表达，但在正常成人组织中不表达，除了睾丸生殖细胞，因此被认为是免疫治疗的靶点。目的探讨慢性髓性白血病(CML)患者细胞中CTA表达的频率及其临床意义。材料与方法采用逆转录聚合酶链式反应(RT-PCR)对10份健康供者外周血和65份CML患者骨髓样本中的8个CTA家族基因(MAGE-A3、MAGE-A4、MAGE-B2、MAGE-C1、BAGE-1、GAGE-2、lag -1和y - eso -1)进行分析。分析了接受常规治疗(羟基脲和infa)患者的11个造血祖干细胞样本和接受酪氨酸激酶抑制剂(伊马替尼、尼洛替尼、达沙替尼)患者的21个样本。结果CTA基因在CML患者中的检出率分别为32.3%、63.0%、1.5%、3.0%、6.1%、20.0%、13.8%、36.9%，分别为MAGE- a3、MAGE- a4、MAGE- b2、MAGE C1、BAGE、GAGE、LAGE和NY-ESO。性别中MAGE-A3基因表达量(p = 0.018)、白细胞中MAGE-C1基因表达量(p = 0.014)、血小板中MAGE-C1基因表达量(p = 0.002)、与血小板相关的LAGE-1基因表达量与临床参数的相关性均有统计学意义(p = 0.001)。接受治疗的患者的造血祖干细胞的表达频率高于新生患者。在接受常规药物(CD)治疗的患者中，MAGE-A3表达频率为50%，TKI组为69.2%;MAGE-A4表达频率为20%，TKI组为53.8%。最后，NY-ESO-1在CD组的发生率为20%，TKI组的发生率为0%。MAGE-A4的表达频率最高，其次是MAGE-A3、NY-ESO-1、GAGE-2、age -1、bag -1、MAGE-B2和MAGE-C1。结论利用分子生物学技术检测CTA基因在LMC、疾病进展监测和化疗耐药患者中具有重要的生物标志物作用。治疗组和新生组CTA表达频率有显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Medica del Hospital General de Mexico

自引率

0.00%

发文量

审稿时长

20 weeks

期刊介绍： The Medical Journal of the Hospital General de Mexico is the official organ of the Medical Society of the Hospital General de Mexico. The journal accepts articles in Spanish or in English on the field of hospital medicine. The journal publishes original articles, clinical cases, reviews articles, history notes, issues on medical education, short communications and editorials at the invitation of the Society. All articles are double blind peer reviewed by at least 2 reviewers and finally classified as accepted or rejected by the Editorial Board.